NASDAQ:HURA TuHURA Biosciences (HURA) Stock Price, News & Analysis $2.11 -0.04 (-1.86%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.19 +0.09 (+4.03%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TuHURA Biosciences Stock (NASDAQ:HURA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TuHURA Biosciences alerts:Sign Up Key Stats Today's Range$2.10▼$2.2150-Day Range$1.97▼$2.7152-Week Range$0.41▼$3.90Volume203,906 shsAverage Volume577,947 shsMarket Capitalization$134.36 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingModerate Buy Company Overview TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies. At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states. This platform enables the identification of previously unrecognized biological pathways and target proteins, supporting both small‐molecule and biologic drug discovery. The technology is designed to accelerate early‐stage research by revealing disease drivers that traditional genomics and transcriptomics methods may overlook. TuHURA is advancing a pipeline of programs in areas such as immunology, neurodegeneration and female health. The company has entered research collaborations with pharmaceutical and academic partners to validate targets and co‐develop lead candidates. These partnerships are helping TuHURA expand its reach into therapeutic areas of high unmet medical need while leveraging external expertise and resources. Founded as a spin‐out from the University of California, Davis technology transfer office, TuHURA Biosciences is headquartered in California and serves a global research community. The company completed its initial public offering on the Nasdaq Capital Market under the ticker HURA in 2022, positioning itself for continued growth and innovation in proteomics‐driven drug discovery.AI Generated. May Contain Errors. Read More TuHURA Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreHURA MarketRank™: TuHURA Biosciences scored higher than 40% of companies evaluated by MarketBeat, and ranked 619th out of 836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingTuHURA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTuHURA Biosciences has a consensus price target of $9.00, representing about 326.5% upside from its current price of $2.11.Amount of Analyst CoverageTuHURA Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about TuHURA Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for TuHURA Biosciences are expected to decrease in the coming year, from ($0.56) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TuHURA Biosciences is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TuHURA Biosciences is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTuHURA Biosciences has a P/B Ratio of 6.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TuHURA Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.11% of the float of TuHURA Biosciences has been sold short.Short Interest Ratio / Days to CoverTuHURA Biosciences has a short interest ratio ("days to cover") of 15.48, which indicates bearish sentiment.Change versus previous monthShort interest in TuHURA Biosciences has recently decreased by 4.93%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTuHURA Biosciences does not currently pay a dividend.Dividend GrowthTuHURA Biosciences does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.94 News SentimentTuHURA Biosciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for TuHURA Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for HURA on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat Follows4 people have added TuHURA Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TuHURA Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders6.06% of the stock of TuHURA Biosciences is held by insiders.Percentage Held by Institutions0.62% of the stock of TuHURA Biosciences is held by institutions.Read more about TuHURA Biosciences' insider trading history. Receive HURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TuHURA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HURA Stock News HeadlinesTuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth ConferenceJuly 22, 2026 | prnewswire.comTuHURA Biosciences (NASDAQ:HURA) Shares Down 1.3% - Time to Sell?July 22, 2026 | americanbankingnews.comElon did WHAT?!Something big is happening beyond SpaceX. Accelerated AI stocks have surged 133%, 217%, and even 320% in just a few months, according to Jason Bodner, founder of Inflection Point. Bodner says the trend hasn't caught mainstream attention yet, even as the technology behind it drives rapid gains for early investors.July 26 at 1:00 AM | Brownstone Research (Ad)TuHURA Biosciences Expands Use of Revolving Credit FacilityJuly 7, 2026 | tipranks.comTuHURA Biosciences, Inc.: TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets ...June 16, 2026 | finanznachrichten.deTuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood ...June 15, 2026 | finance.yahoo.comTuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related CancersJune 15, 2026 | prnewswire.comTuHURA Biosciences Draws on New $50M Credit FacilityMay 29, 2026 | tipranks.comSee More Headlines HURA Stock Analysis - Frequently Asked Questions How have HURA shares performed this year? TuHURA Biosciences' stock was trading at $0.7567 at the beginning of 2026. Since then, HURA stock has increased by 178.8% and is now trading at $2.11. How were TuHURA Biosciences' earnings last quarter? TuHURA Biosciences, Inc. (NASDAQ:HURA) issued its earnings results on Friday, May, 15th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.01. How do I buy shares of TuHURA Biosciences? Shares of HURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2026Today7/26/2026CG 46th Annual Growth Conference8/12/2026Next Earnings (Estimated)8/13/2026AGM 20268/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 HURA's financial health is in the Green zone, according to TradeSmith. HURA has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HURA Previous SymbolNASDAQ:HURA CIK1498382 WebN/A Phone(813) 875-6600Fax604-608-5685EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for TuHURA Biosciences$9.00 High Price Target$10.00 Low Price Target$8.00 Potential Upside/Downside+326.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30.05 million Net MarginsN/A Pretax MarginN/A Return on Equity-156.12% Return on Assets-105.38% Debt Debt-to-Equity RatioN/A Current Ratio1.15 Quick Ratio1.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book6.21Miscellaneous Outstanding Shares63,680,000Free Float59,824,000Market Cap$134.36 million OptionableN/A Beta-0.05 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:HURA) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe comeback story of the century (ticker inside)In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of ...InvestorPlace | SponsoredThe pact that ran the world and dollar just expiredIn 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...Golden Portfolio | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
